Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 20, Issue 10, 2002, Pages 2453-2463

  Witzig, Thomas E ^a   Gordon, Leo I ^a   Cabanillas, Fernando ^a   Czuczman, Myron S ^a   Emmanouilides, Christos ^a   Joyce, Robin ^a   Pohlman, Brad L ^a   Bartlett, Nancy L ^a   Wiseman, Gregory A ^a   Padre, Norman ^a   Grillo López, Antonio J ^a   Multani, Pratik ^a   White, Christine A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IBRITUMOMAB TIUXETAN; RITUXIMAB; YTTRIUM 90;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER GRADING; CANCER IMMUNOTHERAPY; CELL TYPE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSIMETRY; DRUG TOLERABILITY; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; NONHODGKIN LYMPHOMA; OUTCOMES RESEARCH; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD19; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIVER; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; LYMPHOMA, LOW-GRADE; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY; SURVIVAL RATE; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 0037093241     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.11.076     Document Type: Article

References (49)

1. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD 20
2. Molecular cloning of the human B cell CD 20 receptor predicts a hydrophobic protein with multiple transmembrane domains
3. Monoclonal antibody IF5 (anti-CD20) serotherapy of human B cell lymphomas
4. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
5. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
6. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2BS) in patients with recurrent B-cell lymphoma
7. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
8. The anti-tumor effect of monoclonal anti-CD20 antibody (MAB) therapy includes direct antiproliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines
9. Recurrence rates following radiation therapy of nodular and diffuse malignant lymphomas
10. Radioimmunotherapy of human B-cell lymphoma with 90Y-conjugated antiidiotype monoclonal antibody
11. Law and order of radiation sensitivity: Absolute versus relative
12. Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idiotype monoclonal antibodies
13. Comparative biodistribution studies of DTPA-derivative bifunctional chelates for radiometal labeled monoclonal antibodies
14. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma
15. Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01
16. Phase I study of IDEC-Y2B8: 90-Yttrium labeled anti-CD20 monoclonal antibody therapy of relapsed non-Hodgkin's lymphoma
17. Phase I/Il trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma
18. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
19. Clinical experience with preparation of Zevalin (ibritumomab tiuxetan, IDEC Y2B8/IDEC-In2B8) using a radiolabeling kit
20. Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy
21. PCR monitoring of response in patients treated with high-dose chemotherapy for low-grade lymphoma
22. The Functional Assessment of Cancer Therapy Scale: Development and validation of the general measure
23. Phase I/Il 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy: Dosimetry results in relapsed or refractory non-Hodgkin's lymphoma
24. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
25. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma
26. Nonparametric estimation for incomplete observations
27. Prospective randomized controlled study of Zevalin (IDEC-Y2B8) radioimmunotherapy compared to rituximab immunotherapy for B-cell NHL: Report of interim results
28. The International Workshop non-Hodgkin's lymphoma (NHL) response criteria applied to two Zevalin radioimmunotherapy trials
29. Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-I antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma
30. Maximum tolerated dose of 67Cu-2IT-BAT-LYM-I for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: A pilot study
31. Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience
32. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody
33. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue
34. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas
35. Myeloablative radiolabeled antibody therapy with autologous bone marrow transplantation for relapsed B cell lymphomas
36. Phase I/II trial of multiple dose 131iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma
37. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas
38. Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials
39. Response criteria (RC) and quality assurance (QA) of responses in the evaluation of new therapies for patients (pts) with low-grade lymphoma (LG NHL)
40. Reporting outcomes in Hodgkin's disease and lymphoma
41. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas
42. Radiolabeled antibody: Iodine versus radiometal chelates
43. Distribution of absorbed dose around point sources of electrons and beta particles in water and other media
44. Radioimmunotherapy for lymphoma
45. Dosimetric principles of targeted radiotherapy
46. TM for non-Hodgkin's lymphoma
47. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma